JP Morgan Athlete Center of Excellence: athletes need a financial playbook now more than ever These aren’t professional athlete questions. Fortune · Nov 8
US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom US hospital operators are experiencing revenue pressure due to an increase in uninsured patients affecting their operating margins. The expiration of federal subsidies is causing ACA exchange premiums to rise sharply, leading to more patients losing coverage. Major hospital chains are bracing for declines in Medicaid supplemental payments that could… The Economic Times · Nov 5
Nasdaq 100 cracks 5%, wipes out $2 trillion in October as AI spending fears deepen Investor concerns about the high expenditures on artificial intelligence have intensified amidst rising borrowing costs. Major technology companies like Meta, Alphabet, and Microsoft are increasing their capital outlays to strengthen AI infrastructure. The Nasdaq 100 index has already seen a significant decline of more than 5.8% in October. Analysts predict… The Economic Times · Oct 30
Tech Brief (Oct. 27): Unitree Warns of Valuation Risks After Shares Surge More Than 65% Apple’s debut foldable phone suffers hardware and software glitches, Moonshot AI launches more powerful Kimi model Caixin Global · Oct 27
Wall Street Gets Peru's $40B Pitch: Can Its Biggest Investment Push Overcome the $110B Infrastructure Gap Now? Peru's 70-plus-member delegation opened its 19th inPERÚ roadshow in New York, promoting a $40 billion infrastructure pipeline while confronting inflation, El Niño risks and social conflicts. Latin Times · Oct 26
GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan says The China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimates. Improving affordability, generic launches and wider access could drive adoption, though penetration remains low, particularly in India, where cost concerns and cultural resistance to injectable treatments remain key barriers. The Economic Times · Oct 23
Oil Price Predictions: Why Paul Tudor Jones Says Crude Can Gain Another $25 Oil bulls may have another reason to cheer as Paul Tudor Jones bets on higher crude prices. But could another rally give equities a headache? Barchart · Oct 14
JPMorgan Agreed To Scoop This Irish Fintech - Read Why JPMorgan Chase & Co (NYSE:JPM) agreed to acquire Global Shares. Global Shares is an Irish fintech firm whose software helps businesses manage employee stock plans. The financial terms of the transaction remain undisclosed. Founded in 2005, Global Shares manages ~$200 billion in assets, and over 600 clients use its cloud-based platform. JPMorgan looks… Benzinga · Mar 15, 2022
Read Why JP Morgan Sees Apple Poised For Upside Apple Inc (NASDAQ: AAPL) is poised to see "upside" if it can execute and show the growth that it saw in its fiscal first quarter, according to J.P. Morgan analyst Samik Chatterjee. Benzinga · Feb 28, 2022
Should You Buy Goodyear Tire & Rubber on the Dip? The shares of one of the world’s largest tire manufacturers, Goodyear Tire & Rubber (GT), have plunged in price on the company’s disappointing financial guidance. However, according to a J.P. Morgan analyst, the selloff was an ‘overreaction.’ So, the question is, is it worth buying the dip in GT? Keep… StockNews.com · Feb 22, 2022